Childhood malignant diseases: Which is the carnitine's role?

Journal of Pediatric Hematology/Oncology

Volumn 29, Issue 5, 2007, Pages 291-292

  Rogalidou, Maria E ^a   Stiakaki, Eftichia ^a   Evangeliou, Athanasios ^a   Kalmanti, Maria ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CARNITINE; CISPLATIN;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CARDIOMYOPATHY; CHILDHOOD CANCER; DIET SUPPLEMENTATION; FATTY ACID OXIDATION; GLYCOLYSIS; HUMAN; KETOGENIC DIET; MITOCHONDRIAL TOXICITY; PRIORITY JOURNAL; TUMOR GROWTH;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARNITINE; HUMANS; NEOPLASMS;

EID: 34248229313     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318055644b     Document Type: Article

References (14)

1. Bohles H, Evangeliou A, Bervoets K, et al. Carnitine esters in metabolic disease. Eur J Pediatrics. 1994;153(7 suppl 1):S57-S61.
2. Stumpf DA, Parker D, Angelini C. Carnitine deficiency, organic acidemias and Reye's syndrome. Neurology. 1985;35:1041-1045.
3. Duran M, Loof N, Ketting D, et al. Secondary carnitine deficiency. J Clin Chem Clin Biochem. 1990;28:359-363.
4. Evangeliou A, Vlassopoulos D. Carnitine metabolism and deficit - when supplementation is necessary? Curr Pharm Biotechnol. 2003;4:211-219.
5. Peluso G, Nicolai R, Reda E, et al. Cancer and anticancer therapy-induced modifications on metabolism mediated by carnitine system. J Cell Physiol. 2000;182:339-350.
6. Lee MG, Pedersen PL. Glucose metabolism in cancer: importance of transcription factor-DNA interactions within a short segment of the proximal region of the type II hexokinase promoter. J Biol Chem. 2003;278:41047-41058.
7. Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem. 2002;277:23111-23115.
8. Zhou W, Simpson PJ, McFadden JM, et al. Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res. 2003;63:7330-7337.
9. Nebeling LC, Lerner E. Implementing a ketogenic diet based on medium-chain triglyceride oil in pediatric patients with cancer. J Am Diet Assoc. 1995;95:693-697.
10. Yaris N, Akyuz C, Coskun T, et al. Serum carnitine levels of Pediatric cancer patients. Pediatr Hematol Oncol. 2002;19:1-8.
11. Nicula P, Ruohola H, Alhonen-Hongisto L, et al. Carnitine prevents the early mitochondrial damage induced by methyloglyoxal bis (guanylhydrazone) in L1210 leukemia cells. Biochem J. 1985;228:513-516.
12. Graziano F, Bisonni R, Catalano V, et al. Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. Br J Cancer. 2002;86:1854-1857.
13. Chang BJ, Nishikawa M, Sato E, et al. L-carnitine inhibits cisplatin-induced injury of the kidney and small intestine. Arch Biochem Biophys. 2002;405:55-64.
14. Alesci S, De Martino MU, Mirani M, et al. L-carnitine: a nutritional modulator of glucocorticoid receptor functions. FASEB J. 2003;17:1553-1555.